KR20240102128A - Composition for promoting absorption of water soluble vitamins by synbiotic - Google Patents
Composition for promoting absorption of water soluble vitamins by synbiotic Download PDFInfo
- Publication number
- KR20240102128A KR20240102128A KR1020220183888A KR20220183888A KR20240102128A KR 20240102128 A KR20240102128 A KR 20240102128A KR 1020220183888 A KR1020220183888 A KR 1020220183888A KR 20220183888 A KR20220183888 A KR 20220183888A KR 20240102128 A KR20240102128 A KR 20240102128A
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- present
- food
- lactobacillus plantarum
- new
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 229930003231 vitamin Natural products 0.000 title claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 13
- 239000011782 vitamin Substances 0.000 title claims abstract description 13
- 229940088594 vitamin Drugs 0.000 title claims abstract description 13
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 title abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 2
- 235000019722 synbiotics Nutrition 0.000 title 1
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 28
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 25
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 25
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013736 caramel Nutrition 0.000 claims description 3
- -1 flakes Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims 3
- 238000003975 animal breeding Methods 0.000 claims 1
- 239000000686 essence Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 22
- 241000894006 Bacteria Species 0.000 abstract description 20
- 239000006041 probiotic Substances 0.000 abstract description 18
- 235000018291 probiotics Nutrition 0.000 abstract description 18
- 244000068988 Glycine max Species 0.000 abstract description 12
- 235000010469 Glycine max Nutrition 0.000 abstract description 12
- 239000004310 lactic acid Substances 0.000 abstract description 11
- 235000014655 lactic acid Nutrition 0.000 abstract description 11
- 230000000529 probiotic effect Effects 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 235000020712 soy bean extract Nutrition 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 239000003833 bile salt Substances 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000021107 fermented food Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940085298 biotin 10 mg Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/72—Biotin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 신품종 육성 및 재배 연구 결과로 개발한 국내 신품종 대두 늘품콩을 락토바실러스 플란타룸 빈스플로라 1712 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주에 관한 것으로, 구체적으로 늘품콩 사료에서 분리된 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주(미생물 수탁번호 KCTC19014P)에 관한 것이다.
본 발명의 균주는 다양한 탄수화물이 발효능력, 다양한 효소의 생산능력, 항산화 활성, 수용성 비타민 영양소의 흡수 강화의 특성을 갖는 신규 유산균으로, 프로바이오틱스 생균제제, 또는 식품이나 화장품, 그리고 사료에 포함시키거나 발효식품의 발효균으로 매우 유용하다. 를 이용하여 발효시킨 늘품콩 발효추출물을 함유하는 모유두세포 증식 및 생장 촉진용 조성물에 관한 것이다.한 본 발명의 늘품콩은 기존의 대두에 비해 아미노산 함량이 높고 식품 원료로 사용상의 안전성과 안정성이 높아 식품, 건강기능식품, 화장품으로서의 사용이 용이하다.The present invention relates to a new strain of Lactobacillus Plantarum Beansflora 1712, a new domestic soybean variety of soybean, developed as a result of research on new breed breeding and cultivation, and specifically to a new strain of Lactobacillus Plantarum Beansflora 1712 isolated from soybean feed. It relates to the lactic acid bacterium Lactobacillus Plantarum Vinceflora 1712 strain (microorganism accession number KCTC19014P).
The strain of the present invention is a new lactic acid bacterium with the characteristics of fermentation ability of various carbohydrates, production ability of various enzymes, antioxidant activity, and enhanced absorption of water-soluble vitamin nutrients, and can be included or fermented in probiotic probiotic preparations, food, cosmetics, and feed. It is very useful as a food fermentation bacteria. It relates to a composition for promoting the proliferation and growth of hair papilla cells containing a fermented soybean extract fermented using. The neulpum soybeans of the present invention have a higher amino acid content than existing soybeans and are highly safe and stable for use as a food raw material. It is easy to use as food, health functional food, and cosmetics.
Description
본 발명은 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주에 관한 것으로, 구체적으로 늘품콩 사료에서 분리된 신규 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주(미생물 수탁번호 KCTC19014P)에 관한 것이다.The present invention relates to a new strain of lactic acid bacteria Lactobacillus Plantarum Vinceflora 1712, and specifically to a new strain of Lactobacillus Plantarum Beansflora 1712 isolated from soybean feed (microorganism accession number KCTC19014P).
최근 건강에 대한 관심이 높아지면서 장 건강이 주목을 받기 시작했다. 사람의 장에는 약 1조 이상의 세균이 존재하고 있는데, 장내 세균 수는 사람의 몸 속 세포보다 약 10배 이상 많이 존재한다. 장내 세균 군집은 pH, 담즙산, 소화 효소, 그리고 뮤신 등의 내부적인 환경과 영양소와 의약품 등의 외부환경, 그리고 세균 요인에 따라 정략적으로 그리고 정성적으로 계속 변화한다. 일반적으로 유익균은 30%, 유해균은 5~10% 정도 차지하는데 이 중 유익균을 프로바이오틱스(Probiotics)라고 구분한다. Recently, as interest in health has increased, intestinal health has begun to receive attention. There are more than 1 trillion bacteria in the human intestine, and the number of bacteria in the intestine is about 10 times more than the number of cells in the human body. The intestinal bacterial community continues to change quantitatively and qualitatively depending on the internal environment such as pH, bile acids, digestive enzymes, and mucins, the external environment such as nutrients and medicines, and bacterial factors. Generally, beneficial bacteria account for 30% and harmful bacteria account for 5 to 10%. Among these, beneficial bacteria are called probiotics.
건강한 상태에서는 대부분의 세균이 인체에 유익한 작용을 하는 프리바이오틱스로 작용한다. 프리바이오틱스는 충분한 양으로 섭취했을 때 장 기능에 도움을 줄 뿐만 아니라 면역계 활성화, 암 발생의 억제, 과민면역반응의 억제, 소화관의 미생물 균형의 조절 등에 효과가 있는 것으로 보고된 바 있다. In a healthy state, most bacteria act as prebiotics that have beneficial effects on the human body. It has been reported that prebiotics not only help intestinal function when consumed in sufficient amounts, but are also effective in activating the immune system, suppressing cancer development, suppressing hypersensitive immune responses, and regulating the microbial balance in the digestive tract.
프로바이오틱스는 그리스어로 ‘생명을 위한(for life)’ 의미를 지니고 있을 만큼 건강에 도움을 주는 미생물로 정의할 수 있다. 그래서 2,400년전 모든 질병은 장에서 비롯된다는 히포크라테스의 기록처럼 오늘날에도 프로바이오틱스가 많은 연구를 통해 특정 질병과 밀접하게 관련이 있음이 밝혀지면서 이에 대한 관심이 더욱 높아지고 있다. Probiotics can be defined as microorganisms that are beneficial to health, as the word means ‘for life’ in Greek. So, just as Hippocrates wrote 2,400 years ago that all diseases originate from the intestines, interest in probiotics is increasing even today as many studies have shown that they are closely related to specific diseases.
오늘날 연구자들은 프로바이오틱스가 갖는 중요한 생리활성기능을 밝히는 것 뿐만 아니라 새로운 용도의 프로바이오틱스의 발견과 대량 생산 그리고 상품화를 꾸준히 시도하고 있다. 표준화된 방법으로 생산할 수 있는 프로바이오틱스 미생물은 자체로 상업적으로 사용이 가능할 뿐만 아니라 발효식품의 발효균으로 사용 등 활용 범위가 폭넓다. 글고 기존처럼 유제품으로부터 신규 동물성 유산균을 발굴하는 것 뿐만 아니라 내산성, 내담즙성이 강해 장 도달률과 정착성이 높은 것으로 보고된 식물성 유산균을 확보하는 연구도 큰 관심을 받고 있다.Today, researchers are not only uncovering the important physiological functions of probiotics, but are also continuously attempting to discover, mass produce, and commercialize new uses of probiotics. Probiotic microorganisms that can be produced using standardized methods can not only be used commercially on their own, but also have a wide range of applications, including use as fermenting bacteria for fermented foods. In addition to discovering new animal-based lactic acid bacteria from dairy products as before, research to secure vegetable-based lactic acid bacteria, which are reported to have strong acid resistance and bile resistance and thus have a high rate of reaching the intestines and colonization, is also receiving great attention.
이에 본 발명자들은 신규로 발굴한 콩 품종인 늘품콩으로부터 프로바이오틱스의 우수한 특성을 신규 미생물을 스크리닝하였으며, 이의 결과 신규로 식물성 유산균 락토바실러스 플란타룸 빈스플로라 1712 균주가 다양한 탄수화물이 발효능력, 다양한 효소의 생산능력, 항산화 활성, 수용성 비타민 영양소의 흡수 강화 등 우수한 프로바이오틱스의 특성을 갖고 있음을 확인하고 본 발명을 완성하게 되었다. Accordingly, the present inventors screened new microorganisms for the excellent properties of probiotics from the newly discovered soybean variety, Neulpumkong, and as a result, the new vegetable lactic acid bacterium Lactobacillus Plantarum Beansflora 1712 strain has the fermentation ability of various carbohydrates and the production of various enzymes. The present invention was completed after confirming that it has excellent probiotic properties such as production capacity, antioxidant activity, and enhanced absorption of water-soluble vitamin nutrients.
이에, 본 발명자들은 기존의 탈모 관련 제제를 대체할 수 있는 새로운 물질을 연구하던 중, 락토바실러스 플란타룸 빈스플로라 1712(기탁번호) 유산균을 이용하여 발효시킨 늘품콩 발효추출물을 유효성분으로 포함하는 조성물을 인체 유래 모유두세포에 투여했을 때 세포 성장이 촉진됨을 확인함으로써 본 발명을 완성하였다. Accordingly, while researching a new substance that can replace existing hair loss-related preparations, the present inventors discovered a product containing fermented soybean extract fermented using Lactobacillus Plantarum Beansflora 1712 (accession number) lactic acid bacteria as an active ingredient. The present invention was completed by confirming that cell growth was promoted when the composition was administered to human dermal papilla cells.
본 발명의 목적은 락토바실러스 플란타룸 빈스플로라 1712를 이용하여 발효시킨 늘품콩 발효추출물을 포함하는 모유두세포 증식 및 생장 촉진용 조성물을 제공하는 것이다. The purpose of the present invention is to provide a composition for promoting the proliferation and growth of hair papilla cells containing a fermented extract of Neulpum soybean fermented using Lactobacillus Plantarum Beansflora 1712.
따라서 본 발명의 주요 목적은 프로바이오틱스로서의 우수한 특성을 갖는 새로운 균주를 제공하는데 있다. 본 발명의 다른 목적은 상기 균주를 이용한 프로바이오틱스 생균제제, 그리고 식품이나 화장품, 사료에 포함시키거나 발효식품의 발효균으로 매우 유용하다. Therefore, the main purpose of the present invention is to provide a new strain with excellent properties as a probiotic. Another object of the present invention is to make probiotics using the above strain, and it is very useful for inclusion in food, cosmetics, feed, or as a fermenting bacteria for fermented foods.
본 발명의 신규 유산균인 락토바실러스 플란타룸(Lactobacillus plantarum) 빈스플로라 1712 균주는 늘품콩에서 분리되었으며, 미생물은행(KACC : Korean Agricultural Culture Collection)에 미생물 수탁번호 KCTC19014P로 기탁되어 있다. Lactobacillus plantarum Vinceflora 1712 strain, a new lactic acid bacterium of the present invention, was isolated from Neulpoom soybean and deposited in the Microorganism Bank (KACC: Korean Agricultural Culture Collection) under the microorganism accession number KCTC19014P.
본 발명의 신규 유산균 균주의 colony가 충분히 올라온 plate를16s rRNA 염기서열 분석 기관에 의뢰하여 진행한 결과 락토바실러스 플란타룸 속하는 새로운 균주로 확인되었다. 본 발명의 균주는 자일로스, 글루코스, 만노스 등의 탄수화물을 발효할 수 있다. 따라서 이들 탄소원이 함유된 재료를 발효하는데 이용할 수 있다.A plate on which sufficient colonies of the new lactic acid bacteria strain of the present invention had grown was submitted to a 16s rRNA base sequence analysis agency, and as a result, it was confirmed to be a new strain belonging to Lactobacillus plantarum. The strain of the present invention can ferment carbohydrates such as xylose, glucose, and mannose. Therefore, materials containing these carbon sources can be used for fermentation.
본 발명의 균주는 a-갈락토시다제(a-galactosidase), b-글루코시다제(b-glucosidase) 등의 효소를 생산할 수 있다. 따라서 이들 효소의 활성이 필요한 분야에 사용될 수 있다. The strain of the present invention can produce enzymes such as a-galactosidase and b-glucosidase. Therefore, they can be used in fields that require the activity of these enzymes.
본 발명의 균주는 pH 2~3의 위액 환경에서도 생존할 수 있고 담즙염이 높은 농도로 존재하는 조건에서도 생존할 수 있어, 위나 소장 등의 소화기관을 지나는 동안 생존하여 장까지 살아있는 채로 도달할 가능성이 높다. The strain of the present invention can survive in a gastric fluid environment of pH 2-3 and can survive in conditions where bile salts are present at high concentrations, so it has the possibility of surviving while passing through digestive organs such as the stomach and small intestine and reaching the intestines alive. This is high.
본 발명의 균주는 항산화 활성이 우수하여 항산화제 특성을 갖는 프로바이오틱스로 유용하게 활용될 수 있다. The strain of the present invention has excellent antioxidant activity and can be usefully used as a probiotic with antioxidant properties.
본 발명의 균주는 수용성 비타민의 체내 흡수를 강화하는 특성을 가져, 영양소 흡수 강화제로 유용하게 활용될 수 있다. The strain of the present invention has properties that enhance the absorption of water-soluble vitamins in the body, and can be usefully used as a nutrient absorption enhancer.
상기와 같이 본 발명의 균주는 프로바이오틱스로서의 우수한 특징을 가지므로 프로바이오틱스 생균제제로 이용될 수 있다. 이 때 생균제제는 본 발명의 균주 자체 또는 균주의 배양물로 이루어질 수 있으며, 제제화의 용이성을 위해 부형제 등이 첨가된 형태일 수 있다. As described above, the strain of the present invention has excellent characteristics as a probiotic and can be used as a probiotic preparation. At this time, the probiotic may be composed of the strain itself or a culture of the strain of the present invention, and may be in the form of excipients, etc. added for ease of formulation.
또한 본 발명의 균주 또는 이의 배양물은 식품, 건강기능식품, 화장품, 그리고 사료의 재료 또는 첨가제로 사용될 수 있 다. 이 때 배양물은 균체가 포함되지 않은 형태로 이용될 수 있으나, 프로바이오틱스의 효과를 나타내기 위해서는 균체가 포함된 형태로 적용하는것이 바람직하다. Additionally, the strain of the present invention or its culture can be used as an ingredient or additive in foods, health functional foods, cosmetics, and feed. At this time, the culture can be used in a form that does not contain bacteria, but in order to demonstrate the effect of probiotics, it is preferable to apply it in a form that contains bacteria.
또한 본 발명의 균주는 발효식품, 발효화장품, 또는 발효사료의 발효균주로도 사용될 수 있다. 이때 발효식품 또는 발효사료에는 본 발명의 균주가 발효될 수 있는 성분이 함유된 원료를 사용하는 것이 바람직하다. Additionally, the strain of the present invention can also be used as a fermented strain for fermented foods, fermented cosmetics, or fermented feed. At this time, it is preferable to use raw materials containing ingredients that can ferment the strain of the present invention for fermented food or fermented feed.
이하, 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명의 예시를 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다. Hereinafter, the present invention will be described in more detail through examples. Since these examples are merely for illustrative purposes of the present invention, the scope of the present invention is not to be construed as limited by these examples.
[실시예][Example]
1. 방법 1. Method
1-1. 균주의 분리 1-1. Isolation of strains
대한민국 서울시 서울대학교로부터 제공된 늘품콩 샘플을 수집하였다. 사료를 전처리할 장소와 사용할 모든 소모품은 70% 알코올을 이용해 소독하고 오염을 방지하였다. 시료는 불린 늘품콩과 불리지 않는 늘품콩을 사용하여 유산균의 생육 조건 37도에서 약 24시간 동안 발효하였다. Samples of neulpoom bean provided by Seoul National University in Seoul, Korea were collected. The area for pre-processing the feed and all consumables to be used were disinfected with 70% alcohol to prevent contamination. The samples were fermented using soaked and unsoaked soybeans at 37 degrees for the growth of lactic acid bacteria for about 24 hours.
배양액은 각각 멸균된 0.85% NaCl 용액을 사용하여 10³~10? 까지 희석하여, MRS agar 평판배지(BPB 배지)에 희석한 시료를 각각 도말하여 접종하였다. 37도 혐기 조건에서 48시간 배양하여 1개의 균주만 분리될 수 있도록 순수분리 과정을 진행하였다. Each culture medium was incubated at a concentration of 10³~10? using a sterilized 0.85% NaCl solution. After diluting to , each diluted sample was plated and inoculated on MRS agar plate medium (BPB medium). The pure separation process was conducted so that only one strain could be isolated by culturing for 48 hours under anaerobic conditions at 37 degrees.
순수 배양된 균주의 colony가 충분히 올라운 plage를 16s rRNA 염기서열 분석 기관에 의뢰하여 염기서열 분석을 완료하였다. 구체적으로 균주의 게놈 DNA를 추출하고, QIAquick 키트(Qiagen Ltd., Crawley, UK)로 정제하였으며, 유니버셜 프라이머 27F(5'-AGA GTT TGA TCG TGG CTC AG-3') 및 1492R(3'-GCT TAC CTT GTT ACG ACT T-5')을 사용하여 증폭산물의 서열을 분석하였다. NCBI gene bank의 데이터베이스에서 BLAST를 사용하여 16s rRNA 서열을 얼라인 분석하였다. The plage with sufficient colonies of the pure cultured strain was submitted to a 16s rRNA sequence analysis agency and sequence analysis was completed. Specifically, the genomic DNA of the strain was extracted and purified using the QIAquick kit (Qiagen Ltd., Crawley, UK), and universal primers 27F (5'-AGA GTT TGA TCG TGG CTC AG-3') and 1492R (3'-GCT) The sequence of the amplification product was analyzed using TAC CTT GTT ACG ACT T-5'). The 16s rRNA sequence was aligned and analyzed using BLAST in the NCBI gene bank database.
다음으로 사용 가능한 본 균주만 선별하여 MRS agar 배지에 접종하여 배양한 후 colony가 충분히 올라왔을 때 stock을 제조하여 완성하였다. Next, only the strains that could be used were selected, inoculated on MRS agar medium, cultured, and when enough colonies had grown, a stock was prepared and completed.
1-2. pH 환경에 대한 저항성 분석1-2. Resistance analysis to pH environment
Ilavenil 등(J Sci Food Agric. 96:593-601)의 방법에 따라 락토바실러스 플란타룸 빈스폴로라 1712 균주의 낮은 pH에 대한 내성을 조사하였다. 배양된 균주를 다양한 pH의 MRS 배양액에 접종하고, 37℃에서 48시간 배양하였다. 배양 후 각 배양액 100㎕를 pour plate 방법으로 MRS 배지에 접종하고, 37℃에서 48시간 배양하여 콜로니를 계수하였다.Resistance to low pH of Lactobacillus plantarum Vinspolora 1712 strain was investigated according to the method of Ilavenil et al. (J Sci Food Agric. 96:593-601). The cultured strains were inoculated into MRS cultures of various pH and cultured at 37°C for 48 hours. After culturing, 100㎕ of each culture was inoculated into MRS medium using the pour plate method, and the colonies were counted by culturing at 37°C for 48 hours.
1-3. 위의 pH에 대한 내성 분석1-3. Tolerance analysis for above pH
Charteris 등(J Appl Microbiol. 84:759-768)의 방법에 따라 락토바실러스 플란타룸 빈스폴로라 1712 균주의 위액에 대한 저항성을 조사하였다. 펩신(pepsin, 3㎎/㎖), 0.5%(w/v) NaCl 및 물을 사용하여 위액을 준비하고, 1mol/L HCl을 사용하여 pH를 약 2 및 3으로 맞추었다. 30㎖의 균주 배양액을 4℃에서 6000xg로 20분간 원심분리하고, 펠렛을 수득하여 K2HPO4(50mmol/L, 6.5pH)로 3회 세척하였다. 펠렛을 재현탁한 다음 1㎖의 현탁액을 9㎖의 위액과 혼합하고 37℃ 에서 3시간 배양하였다. 배양전 및 배양후의 총 생균을 계수하였다.Resistance to gastric juice of Lactobacillus plantarum Vincellora 1712 strain was investigated according to the method of Charteris et al. (J Appl Microbiol. 84:759-768). Gastric fluid was prepared using pepsin (3 mg/ml), 0.5% (w/v) NaCl, and water, and the pH was adjusted to about 2 and 3 using 1 mol/L HCl. 30 ml of strain culture was centrifuged at 6000xg for 20 minutes at 4°C, and the pellet was obtained and washed three times with K2HPO4 (50 mmol/L, 6.5 pH). After resuspending the pellet, 1 ml of suspension was mixed with 9 ml of gastric fluid and incubated at 37°C for 3 hours. Total viable bacteria before and after culture were counted.
1-4. 농축된 담즙염 환경에 대한 내성 분석1-4. Analysis of tolerance to concentrated bile salt environment
락토바실러스 플란타룸 빈스폴로라 1712 균주의 배양액을 0.5% 소듐 디옥시콜레이트 및 0.3% 옥스갈(DCA Sigma, St Louis, MO, USA)과 같은 담즙 염이 함유된 MRS 액체배지에 접종하고 37℃에서 배양하였다. 일정 시간 간격(24시간 및 48시간 후)으로 배양 액을 분취하고 600nm에서 흡광도를 측정하였다. 담즙염을 첨가하지 않은 MRS 배지를 대조군으로 사용하였다.The culture of Lactobacillus Plantarum Vinspolora 1712 strain was inoculated into MRS liquid medium containing bile salts such as 0.5% sodium deoxycholate and 0.3% Oxgal (DCA Sigma, St Louis, MO, USA) and incubated at 37°C. It was cultured in . Culture liquid was aliquoted at regular time intervals (after 24 and 48 hours) and absorbance was measured at 600 nm. MRS medium without bile salts was used as a control.
1-5. DPPH법에 의한 자유라디컬 소거력 분석 1-5. Free radical scavenging power analysis by DPPH method
Li 등(Food Chemistry, 135:1914-1919)의 방법에 약간의 변경을 적용하여 락토바실러스 플란타룸 빈스폴로라 1712 균주의 DPPH(2,2-Diphenyl-1- picrylhydrazyl) 라디칼 소거활성을 측정하였다. The DPPH (2,2-Diphenyl-1-picrylhydrazyl) radical scavenging activity of Lactobacillus plantarum Vincellora 1712 strain was measured by applying a slight change to the method of Li et al. (Food Chemistry, 135:1914-1919). .
다양한 농도(10, 20, 30, 40 및 50㎍)의 균주 배양액(10 9 [0071] CFU/㎖)을 1㎖의 DPPH 용액(0.05mM)과 혼합하고, 상온 에서 30분간 암실에서 배양하였다. DPPH 용액을 대조군(control)으로 사용하였다. 메탄올과 균주세포의 혼합액 은 Blank로 사용하였다. 흡광도는 517nm에서 측정하였다. DPPH 라디칼 소거활성은 다음 계산식으로 계산하였다Various concentrations (10, 20, 30, 40, and 50 μg) of the strain culture (10 9 CFU/ml) were mixed with 1 ml of DPPH solution (0.05mM) and incubated in the dark at room temperature for 30 minutes. DPPH solution was used as a control. The mixture of methanol and strain cells was used as a blank. Absorbance was measured at 517 nm. DPPH radical scavenging activity was calculated using the following formula:
DPPH 소거활성(%) = [(Sample - Blank) / Control] x 100DPPH scavenging activity (%) = [(Sample - Blank) / Control] x 100
1-6. 수용성 비타민 흡수 강화능력 분석1-6. Analysis of water-soluble vitamin absorption enhancement ability
본 발명의 락토바실러스 플란타룸 빈스폴로라 1712 균주의 수용성 비타민 흡수 강화 능력이 있는지 확인하기 위하여 다음의 실험을 진행하였다. 생후 6주령 C57Bl/6계 수컷 흰쥐를 일반 고형 사료로 3일간 적응 시킨 후, 하기 2개 군(대조군, 실험군1, 2)으로 분류하여, 실험 식이를 4일간 공급하였다. 이후 혈액을 채취하여 HPLC 분석을 통해 혈액 내 비오틴의 함량을 측정하였다. The following experiment was conducted to confirm whether the Lactobacillus plantarum Vinspolora 1712 strain of the present invention has the ability to enhance water-soluble vitamin absorption. Six-week-old C57Bl/6 male rats were acclimated to regular solid feed for 3 days, then divided into the following two groups (control group, experimental group 1 and 2) and fed the experimental diet for 4 days. Afterwards, blood was collected and the biotin content in the blood was measured through HPLC analysis.
대조군 : 일반 고형 사료Control group: regular solid feed
실험군1 : 일반 고형 사료+비오틴10mg/kgExperimental group 1: General solid feed + biotin 10mg/kg
실험군2 : 일반 고형사료 + 비오틴10mg/kg+락토바실러스 플란타룸 빈스폴로라 1712 균주 1x10? 농도 분말 Experimental group 2: General solid feed + biotin 10mg/kg + Lactobacillus Plantarum Vinspolora 1712 strain 1x10? concentration powder
2. 결과2. Results
2-1. 분리 및 스크리닝2-1. Separation and screening
뚜렷한 형태학적 특성을 바탕으로 락토바실러스 플란타룸 빈스폴로라 1712 균주를 분리하였다. 16S rRNA 서열 분석을 통해 락토바실러스 플란타룸 빈스폴로라 1712의 분자적 특성을 분석한 결과, Lactobacillus plantarum에 속하는 것으로 나타났다. 이 16S rRNA 서열은 미생물 수탁번호 KCTC19014P로 기탁되었다. Lactobacillus Plantarum Vincellora 1712 strain was isolated based on distinct morphological characteristics. As a result of analyzing the molecular characteristics of Lactobacillus Plantarum Vincellora 1712 through 16S rRNA sequence analysis, it was found to belong to Lactobacillus plantarum. This 16S rRNA sequence was deposited under the microorganism accession number KCTC19014P.
2-2. 산성조건 및 담즙염 내성2-2. Acidic conditions and bile salt tolerance
본 발명의 락토바실러스 플란타룸 빈스폴로라 1712 균주는 다양한 pH 환경에 내성이 있는지 측정한 결과, pH 2 및 pH3의 위액 환경에서도 우수한 내성을 나타내었다. 또한 0.3% oxgall 및 0.5% sodium deoxycholate의 높은 농도의 담즙염 환경에서도 우수한 내성을 나타내었다 (도1 참조)As a result of measuring whether the Lactobacillus plantarum Vinspolora 1712 strain of the present invention is resistant to various pH environments, it showed excellent resistance even in gastric fluid environments of pH 2 and pH 3. It also showed excellent tolerance even in a bile salt environment with high concentrations of 0.3% oxgall and 0.5% sodium deoxycholate (see Figure 1).
2-3. 항산화 효과2-3. Antioxidative effect
본 발명의 락토바실러스 플란타룸 빈스폴로라 1712 균주는 DPPH 라디컬 소거능을 측정한 결과, 대표적인 항산화 영양소인 비타민C에 비해 자유라디칼 소거활성이 우수한 것으로 나타났다 (도2 참조)As a result of measuring the DPPH radical scavenging ability of the Lactobacillus plantarum Vinspolora 1712 strain of the present invention, it was found to have superior free radical scavenging activity compared to vitamin C, a representative antioxidant nutrient (see Figure 2).
2-4. 수용성 비타민 흡수 강화 효과2-4. Strengthening effect of water-soluble vitamin absorption
비오틴을 섭취하지 않은 대조군에 비하여 비오틴을 섭취한 실험군1 내지 실험군2 혈액 내 비오틴 함량이 증가한 것을 알 수 있다. 특히, 본 발명의 락토바실러스 플란타룸 빈스폴로라 1712 균주를 투여한 실험군2는 실험군1에 비해 혈액 중 비오틴 농도가 약 33% 증가한 것을 확인할 수 있다. 이러한 결과를 통해 본 발명의 락토바실러스 플란타룸 빈스폴로라 1712 균주가 비오틴의 생체이용률을 높이는 효과가 있음을 확인할 수 있다 (도3 참조) It can be seen that the biotin content in the blood of experimental groups 1 to 2 that consumed biotin increased compared to the control group that did not consume biotin. In particular, it can be seen that the biotin concentration in the blood of experimental group 2 administered with the Lactobacillus plantarum Vinspolora 1712 strain of the present invention increased by about 33% compared to experimental group 1. Through these results, it can be confirmed that the Lactobacillus plantarum Vinspolora 1712 strain of the present invention is effective in increasing the bioavailability of biotin (see Figure 3)
상기 목적을 달성하기 위하여, 락토바실러스 플란타룸 빈스플로라 1712를 이용하여 발효시킨 늘품콩 발효추출물을 제공한다. 이하 본 발명에 따른 조성물을 상세히 설명하기로 한다.In order to achieve the above object, a fermented extract of Neulpoom soybean fermented using Lactobacillus Plantarum Beansflora 1712 is provided. Hereinafter, the composition according to the present invention will be described in detail.
본 발명은 다양한 변경을 시도할 수 있고 여러 가지 형태를 가질 수 있는 바, 실시 예들을 본문에 상세하게 설명하고자 한다. 그러나 이는 본 발명의 특정한 개시 형태에 대하 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. Since the present invention can be modified in various ways and can take on various forms, embodiments will be described in detail in the text. However, this is not intended to limit the present invention to a specific disclosed form, and should be understood to include all changes, equivalents, and substitutes included in the spirit and technical scope of the present invention.
본 발명에 따른 수용성 비타민 흡수 강화용 조성물은 락토바실러스 플란타룸 빈스폴로라 1712 균주를 포함한 것으로써 수용성 비타민의 생체 내 흡수를 촉진시키고 생체 이용률을 증가시킬 수 있다.The composition for enhancing the absorption of water-soluble vitamins according to the present invention contains Lactobacillus Plantarum Vinspolora 1712 strain and can promote absorption of water-soluble vitamins in vivo and increase bioavailability.
또한, 본 발명에 따른 수용성 비타민을 포함하는 식품 조성물은 다양한 제형(정제, 캡슐, 분말, 액상, 과립, 환, 편상, 페이스트상, 시럽, 겔, 젤리, 카라멜, 구미, 바 등)으로 구현될 수 있으므로 섭취 편리성이 증대되어 소비자의 기호를 충족시킬 수 있으며, 성분 배합 비율상의 제한을 받지 않으므로 고함량 비타민 제제 또는 복합 기능을 가지는 건강기능식품으로 제조될 수 있다. In addition, the food composition containing water-soluble vitamins according to the present invention can be implemented in various dosage forms (tablets, capsules, powders, liquids, granules, pills, flakes, pastes, syrups, gels, jellies, caramels, gummies, bars, etc.) Therefore, the convenience of ingestion increases, satisfying consumer preferences, and since there are no restrictions on the ingredient mixing ratio, it can be manufactured as a high-content vitamin preparation or health functional food with multiple functions.
도1은 산성조건 및 담즙염 내성에 대한 결과이다.
도2는 항산화 효능을 측정한 결과이다.
도3은 수용성 비타민인 비오틴의 흡수 촉진에 관한 결과이다. Figure 1 shows the results for acidic conditions and bile salt tolerance.
Figure 2 shows the results of measuring antioxidant efficacy.
Figure 3 shows the results of promoting absorption of biotin, a water-soluble vitamin.
이에, 본 발명자들은 기존의 탈모 관련 제제를 대체할 수 있는 새로운 물질을 연구하던 중, 락토바실러스 플란타룸 빈스플로라 1712(기탁번호) 유산균을 이용하여 발효시킨 늘품콩 발효추출물을 유효성분으로 포함하는 조성물을 인체 유래 모유두세포에 투여했을 때 세포 성장이 촉진됨을 확인함으로써 본 발명을 완성하였다. Accordingly, while researching a new substance that can replace existing hair loss-related preparations, the present inventors discovered a product containing fermented soybean extract fermented using Lactobacillus Plantarum Beansflora 1712 (accession number) lactic acid bacteria as an active ingredient. The present invention was completed by confirming that cell growth was promoted when the composition was administered to human dermal papilla cells.
본 발명의 목적은 락토바실러스 플란타룸 빈스플로라 1712를 이용하여 발효시킨 늘품콩 발효추출물을 포함하는 모유두세포 증식 및 생장 촉진용 조성물을 제공하는 것이다. The purpose of the present invention is to provide a composition for promoting the proliferation and growth of hair papilla cells containing a fermented extract of Neulpum soybean fermented using Lactobacillus Plantarum Beansflora 1712.
따라서 본 발명의 주요 목적은 프로바이오틱스로서의 우수한 특성을 갖는 새로운 균주를 제공하는데 있다. 본 발명의 다른 목적은 상기 균주를 이용한 프로바이오틱스 생균제제, 그리고 식품이나 화장품, 사료에 포함시키거나 발효식품의 발효균으로 매우 유용하다. Therefore, the main purpose of the present invention is to provide a new strain with excellent properties as a probiotic. Another object of the present invention is to make probiotics using the above strain, and it is very useful for inclusion in food, cosmetics, feed, or as a fermenting bacteria for fermented foods.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220183888A KR20240102128A (en) | 2022-12-26 | 2022-12-26 | Composition for promoting absorption of water soluble vitamins by synbiotic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220183888A KR20240102128A (en) | 2022-12-26 | 2022-12-26 | Composition for promoting absorption of water soluble vitamins by synbiotic |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240102128A true KR20240102128A (en) | 2024-07-03 |
Family
ID=91899957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220183888A KR20240102128A (en) | 2022-12-26 | 2022-12-26 | Composition for promoting absorption of water soluble vitamins by synbiotic |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240102128A (en) |
-
2022
- 2022-12-26 KR KR1020220183888A patent/KR20240102128A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100367553B1 (en) | A Method for Preparing Functional Cultures | |
CN101278702B (en) | Novel microbial feed additive and method of producing the same | |
CN103005159A (en) | Preparation method of ginkgo leaf biological feed additive | |
CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
CN102618452B (en) | Preparation method, composition and application of lactobacillus salivarius and its metabolites | |
KR102562507B1 (en) | Novel lactobacillus paracasei subsp. tolerans wikim0148 with potent anti-inflammatory activity and uses thereof | |
JP2023547056A (en) | Novel Bacillus coagulans CC strain producing α-glucosidase inhibitor | |
KR102251295B1 (en) | A composition for preventing or relieving hangover of the comprising heat-killed lactobacillus salivarius v133 as an active ingredient | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
CN111685235B (en) | Preparation method of lactobacillus plantarum fermented liquid complete feed for piglets | |
KR102130646B1 (en) | Novel lactobacillus salivarius and feed additives for aquacultural fish and crustacea comprising the same | |
KR102234499B1 (en) | Novel Lactobacillus plantarum KCC-35 | |
KR102251294B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the comprising heat-killed lactobacillus salivarius v133 as an active ingredient | |
JP3520012B2 (en) | Composition suitable as a nutrient supplement and for treating intestinal disorders and modifying the bacterial flora | |
KR100910657B1 (en) | New Lactobacillus butneri and uses thereof | |
KR101670955B1 (en) | Feed for farming-fish and Farming-fish farmed using that | |
CN114921383B (en) | Probiotic preparation with cholesterol removal function and preparation method thereof | |
KR20240102128A (en) | Composition for promoting absorption of water soluble vitamins by synbiotic | |
KR102262646B1 (en) | A composition for preventing or relieving hangover of the comprising heat-killed lactobacillus plantarum v135 as an active ingredient | |
KR102407131B1 (en) | Method for preparing a probiotic composition for feed to improve body weight gain or immunity | |
KR102160918B1 (en) | Probiotics for feed including microbe | |
KR20220162284A (en) | A composition for increased activity of alcohol and acetaldehyde degrading enzymes of the comprising heat-killed lactobacillus plantarum v135 as an active ingredient | |
WO2017188157A1 (en) | Agent for regulating composition ratio of intestinal bacterial flora, drug, food, drink and method for regulating composition ratio of intestinal bacterial flora | |
KR102218224B1 (en) | Cosmetic composition for preventing or improving skin inflammation or skin aging comprising fermented product of Ligularia stenocephala leaf as an active ingredient | |
CN108464509B (en) | Application of novel lactobacillus fermentum in food field |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20221226 |
|
PA0201 | Request for examination |
Patent event code: PA02011R01I Patent event date: 20221226 Comment text: Patent Application |
|
PG1501 | Laying open of application |